Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22407708 | 0.80 | KDM4E (0.70) | ALDH1A1TSHRLMNAKDM4EHSD17B10 | |
| SCHEMBL22407646 | 0.79 | ALDH1A1 (0.53) | ALDH1A1TSHRDRD4LMNAKDM4E | |
| SCHEMBL22407669 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TSHRDRD4LMNAKDM4E | |
| SCHEMBL22409694 | 0.78 | ALDH1A1 (0.55) | ALDH1A1TSHRDRD4LMNAMEN1 | |
| SCHEMBL22407644 | 0.78 | SCN4A (0.51) | ALDH1A1TSHRDRD4LMNAKDM4E | |
| Pyrrocaine SCHEMBL25718 | 0.78 | MEN1 (0.70) | ALDH1A1DRD4LMNAKDM4EMEN1 | |
| SCHEMBL22407651 | 0.78 | KDM4E (0.61) | ALDH1A1TSHRLMNAKDM4EHSD17B10 | |
| SCHEMBL22407740 | 0.76 | MEN1 (0.73) | ALDH1A1DRD4LMNAKDM4EMEN1 | |
| Pincainide SCHEMBL2110148 | 0.76 | MEN1 (0.73) | ALDH1A1DRD4LMNAKDM4EMEN1 | |
| Pyrrocaine SCHEMBL10757216 | 0.76 | MEN1 (0.68) | ALDH1A1DRD4LMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3938345-B1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11603355-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3938345-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210061763-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2020185830-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885TSHR 4055/4885DRD4 3107/4885 |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885TSHR 4055/4885DRD4 3107/4885 |
| US-11603355-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885TSHR 4055/4885DRD4 3107/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885TSHR 4055/4885DRD4 3107/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885TSHR 4055/4885DRD4 3107/4885 |
| US-20210061763-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885TSHR 4055/4885DRD4 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.